DOCSLIB.ORG

Cyclooxygenase Selectivity of Nonsteroidal Anti-Inflammatory Drugs and Risk of Stroke

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cyclooxygenase Selectivity of Nonsteroidal Anti-Inflammatory Drugs and Risk of Stroke ORIGINAL INVESTIGATION Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke Mendel D. M. Haag, PharmD; Michiel J. Bos, MD; Albert Hofman, MD, PhD; Peter J. Koudstaal, MD, PhD; Monique M. B. Breteler, MD, PhD; Bruno H. C. Stricker, MB, PhD Background: In clinical trials, cyclooxygenase (COX)- unspecified). Current users of nonselective (HR, 1.72; 95% 2–selective nonsteroidal anti-inflammatory drugs confidence interval [CI], 1.22-2.44) and COX-2–selective (NSAIDs) were associated with an increased risk of throm- (HR, 2.75; 95% CI, 1.28-5.95) NSAIDs had a greater risk boembolic events. We studied the association between of stroke, but not users of COX-1–selective NSAIDs (HR, NSAID use and risk of stroke in the prospective, popu- 1.10; 95% CI, 0.41-2.97). Hazard ratios (95% CIs) for is- lation-based Rotterdam Study. chemic stroke were 1.68 (1.05-2.69) for nonselective and 4.54 (2.06-9.98) for COX-2–selective NSAIDs. For indi- Methods: We followed 7636 persons free of stroke at vidual NSAIDs, current use of the nonselective naproxen baseline (1991-1993) for incident stroke until Septem- (HR, 2.63; 95% CI, 1.47-4.72) and the COX-2–selective ro- ber 2004. Data on all filled prescriptions came from phar- fecoxib (HR, 3.38; 95% CI, 1.48-7.74) was associated with macy records. With Cox regression models, we calcu- a greater risk of stroke. Hazard ratios (95% CIs) for diclo- lated crude and adjusted hazard ratios (HRs) of stroke fenac (1.60 [1.00-2.57]), ibuprofen (1.47 [0.73-3.00]), and for time-dependent current use, compared with never use, celecoxib (3.79 [0.52-27.6]) were greater than 1.00 but were of NSAIDs grouped according to COX selectivity (COX-1 not statistically significant. selective, nonselective, and COX-2 selective) and indi- vidual NSAIDs. Conclusions: In the general population, we found a greater risk of stroke with current use of nonselective and Results: At baseline, the mean age of the study sample COX-2–selective NSAIDs. The risk of stroke was not lim- was 70.2 years, and 61.3% were female. During 70 063 per- ited to the use of COX-2–selective NSAIDs. son-years of follow-up (mean, 9.2 years), 807 persons de- veloped a stroke (460 ischemic, 74 hemorrhagic, and 273 Arch Intern Med. 2008;168(11):1219-1224 N CLINICAL TRIALS, THE USE OF CY- risk of ischemic stroke was found for some clooxygenase (COX)-2–selective COX-2–selective NSAIDs, but this was also nonsteroidal anti-inflammatory found for the nonselective NSAID diclo- drugs (NSAIDs) has been associ- fenac.11 Predominantly, null findings were ated with an increased risk of car- reported in 4 studies that investigated the Idiovascular events and death.1-5 Most of outcome of hemorrhagic stroke.6,8-10 the post hoc analyses of the trials focused It is supposed that selective inhibition on combined cardiovascular or cerebro- of the COX-2 enzymes by the COX-2– vascular events as the end point, without selective NSAIDs induces a prothrom- botic state, unlike NSAIDs that inhibit COX-2 to a lesser degree and additionally CME available online at inhibit COX-1.12-14 However, the cardio- Author Affiliations: www.jamaarchivescme.com vascular risk observed for the various COX- Departments of Epidemiology and questions on page 1133 2–selective NSAIDs has not been consis- and Biostatistics (Drs Haag, Bos, tent in all clinical trials.15 In a recent Hofman, Koudstaal, Breteler, further specification of the risk of stroke. placebo-controlled trial, the non–COX-2– and Stricker), Neurology Moreover, few observational studies have selective NSAID naproxen sodium was as- (Drs Bos and Koudstaal), and investigated the association between NSAID sociated with an increased cardiovascular Internal Medicine (Dr Stricker), use and the risk of stroke.6-11 Of these, one 4 Erasmus Medical Center, risk. Evidence from observational studies Rotterdam, the Netherlands; nested case-control study showed that cur- has also shown that NSAIDs differ in their 16-18 and Inspectorate for Health rent NSAID use was associated with a potential to cause cardiovascular events. Care, The Hague, the greater risk of ischemic stroke.7 In an- In all, it remains inconclusive if the greater Netherlands (Dr Stricker). other nested case-control study, a greater risk of cardiovascular events is specific for (REPRINTED) ARCH INTERN MED/ VOL 168 (NO. 11), JUNE 9, 2008 WWW.ARCHINTERNMED.COM 1219 ©2008 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 DRUG EXPOSURE Table 1. Classification of NSAIDs According to COX-Selective Properties and Total Person-Months of Complete information on all filled prescriptions for all per- Exposure During Follow-up sons was obtained in automated format from the pharmacies. This included the product name, international nonpropri- NSAID Class Person-Months of Exposure etary name, Anatomical Therapeutic Chemical code, total num- COX-1–selective NSAIDs ber of delivered units (eg, tablets or capsules), prescribed daily Indometacine 2181.0 number of units, date of delivery, and drug dosage. The dura- Piroxicam 3108.9 tion of a prescription was calculated as the total number of de- Ketoprofen 1306.3 livered units divided by the prescribed daily number of units. Flurbiprofen 222.4 Drug dosage was defined by the defined daily dose (DDD), the Apazone 272.5 recommended daily dosage of a drug taken by adults for the Nonselective NSAIDs main indication of the drug. Diclofenaca 15 126.7 Based on data from in vitro and clinical studies, NSAIDs were Naproxen 6776.9 classified as COX-1 selective, nonselective, and COX-2 selec- Ibuprofen 8208.6 tive according to their relative selectivity for the COX-1 and Nabumetone 1008.2 COX-2 enzymes at therapeutic dosages (Table 1).20-26 For some Sulindac 467.6 NSAIDs, COX selectivity is unknown or equivocal (ie, benzy- COX-2–selective NSAIDs damine hydrochloride, tiaprofenic acid, tolfenamic acid, phen- Rofecoxib 1882.2 ylbutazone, tenoxicam, and aceclofenac). Celecoxib 342.6 Salicylates (ie, acetylsalicylic acid and carbasalate calcium) Meloxicam 767.0 Etoricoxib 49.8 are pharmacologically related to NSAIDs and inhibit platelet Valdecoxib 12.6 aggregation via COX-1; although, contrary to NSAIDs, their ef- fects are irreversible.27,28 On these grounds, salicylates could Abbreviations: COX, cyclooxygenase; NSAIDs, nonsteroidal be regarded as COX-1–selective NSAIDs; however, they are anti-inflammatory drugs. mostly prescribed at a low dose as platelet inhibitors for the a Includes combination products of diclofenac. prevention of cardiovascular disease and stroke. We did not include salicylates in the COX-1–selective NSAID group for the following reasons: (1) they are indicated for stroke preven- COX-2–selective NSAIDs or whether other pharmacologi- tion; (2) NSAID use is cautioned in persons already using sa- licylates because of the increased risk of gastrointestinal tract cal properties of NSAIDs could cause these detrimental bleeding; and (3) some NSAIDs possibly antagonize the plate- effects. let inhibition induced by salicylates.27,28 This might obscure the We investigated the association between NSAID use protective effect of salicylates. Because of these potential sources and the risk of incident stroke in a large, prospective, of confounding by salicylates, all analyses were adjusted for the population-based cohort study and whether any ob- current use of salicylates, and the effect of salicylates on the served association was restricted to COX-2–selective association between NSAID use and stroke was studied through NSAIDs. stratification. METHODS DIAGNOSIS OF STROKE STUDY POPULATION A history of stroke at the time of enrollment into the Rotter- dam Study was assessed by asking “did you ever suffer from a The Rotterdam Study is a prospective, population-based co- stroke, diagnosed by a physician?” Positive answers to this ques- hort study of age-related disorders.19 The medical ethics com- tion were verified by reviewing the medical records. A history mittee of the Erasmus Medical Center, Rotterdam, the Neth- of transient ischemic attack was also assessed during the base- erlands, approved the study. Between 1990 and 1993, all persons line interview. After enrollment into the Rotterdam Study, par- 55 years or older living in Ommoord, a district of Rotterdam, ticipants were continuously monitored for all major events, in- were invited to participate. Of the 10 275 eligible persons, 7983 cluding cerebrovascular disease, through automated linkage of (77.7%) signed informed consent. Of these individuals, 7722 the study database with files from general practitioners. Infor- were free of stroke at baseline. Follow-up examinations were mation on vital status was obtained at regular intervals from conducted in 1993 to 1994, 1997 to 1999, and 2000 to 2004. the municipal authorities in Rotterdam. When an event or death In addition, the cohort was continuously monitored for major had been reported, additional information was obtained from disease outcomes and death through linkage with records from the general practitioner and from information in the hospital general practitioners and bimonthly updates from the munici- records (including brain imaging) and discharge letters in the pality records. This resulted in a virtually complete follow-up case of admittance or referral. In addition, nursing home phy- for stroke. Nearly all persons (99.7%) were registered at 1 or sicians’ files and files from general practitioners of partici- more of 7 automated pharmacies serving the Ommoord area. pants who moved out of the district were scrutinized. Re- Of these pharmacies, records of all filled prescriptions were avail- search physicians discussed information on all potential strokes able as of January 1, 1991. To ensure at least a 6-month his- and transient ischemic attacks with an experienced neurolo- tory of medication use, we excluded 86 persons for whom fol- gist to verify all diagnoses while blinded to drug exposure.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Aggressive Imaging in Young Children on Antithrombotic Therapy With
    American Journal of Emergency Medicine 37 (2019) 972–1004 Contents lists available at ScienceDirect American Journal of Emergency Medicine journal homepage: www.elsevier.com/locate/ajem Correspondence Aggressive imaging in young children on Low molecular weight heparin (LMWH) is the most commonly used antithrombotic therapy with minor traumatic drug for acute VTE in pediatric patients [12,13]. A review reported of head injury 308 children receiving therapeutic doses LMWH for the treated of VTE, nine (2.9%) had a major bleeding, and 72 (23.4%) a minor bleeding Clinical decision rules have been developed to guide clinicians to [14]. In 133 children receiving prophylactic doses of LMWH, one (0.8%) perform or to omit a CT scan in children with minor traumatic head in- had a major bleeding, and four (3.0%) a minor bleeding. These bleedings jury (MTHI) [1-3]. These guidelines do not define the use of antithrom- occurred all spontaneously without a traumatic cause. Vitamin K antag- botic therapy as a major risk factor for intracranial pathology in young onists (VKA) include warfarin, acenocoumarol and phenprocoumon. children, in contrast to children of six years and older and adults, The most common VKA used in the pediatric setting is warfarin [13]. where this is an indication to perform a CT scan. Risk of major bleeding varies including 0.5% per patient year reported A two-year-old boy on antithrombotic treatment fell on the back of in a large cohort study versus 12.2% in a randomized controlled trial of his head from a one-meter high slide.
    [Show full text]
  • Statistical Analysis Plan – Part 1
    NCT03251482 Janssen Research & Development Statistical Analysis Plan – Part 1 A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery Protocol 64179375THR2001; Phase 2 JNJ-64179375 Status: Approved Date: 18 October 2017 Prepared by: Janssen Research & Development, LLC Document No.: EDMS-ERI-148215770 Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP). Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or confidential. 1 Approved, Date: 18 October 2017 JNJ-64179375 NCT03251482 Statistical Analysis Plan - Part 1 64179375THR2001 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................... 2 LIST OF IN-TEXT TABLES AND FIGURES ...............................................................................................
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff
    Harmonized Tariff Schedule of the United States (2019) Revision 11 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 11 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0286160 A1 Gilbert Et Al
    US 2010O286160A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0286160 A1 Gilbert et al. (43) Pub. Date: Nov. 11, 2010 (54) SUBSTITUTED PIPERAZINES AS CB1 Related U.S. Application Data ANTAGONSTS (60) Provisional application No. 60/946,896, filed on Jun. (75) Inventors: Eric J. Gilbert, Scotch Plains, NJ 28, 2007. (US); William J. Greenlee, Teaneck, NJ (US); Sarah Wei Li, Publication Classification Belle Mead, NJ (US); Michael W. (51) Int. Cl. Miller, Scotch Plains, NJ (US); A 6LX 3L/2197 (2006.01) Jack D. Scott, Scotch Plains, NJ C07D 24I/04 (2006.01) (US); Adrew Stamford, Chatham C07D 403/2 (2006.01) Township, NJ (US); Chander C07D 24I/02 (2006.01) Shekher Celly, Colonia, NJ (US) C07D 40/12 (2006.01) C07D 40/4 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) MERCK PATENT DEPARTMENT (K-6-1, 1990) (52) U.S. Cl. .................... 514/252.11:544/400: 544/372: 2000 GALLOPNGHILL ROAD 544/370; 544/357: 514/254.01: 514/254.05; KENILWORTH, NJ 07033-0530 (US) 514/252.12:544/360; 514/253.13:544/364; 514/253.09 (73) Assignee: Intervet Inc. (57) ABSTRACT (21) Appl. No.: 12/665,253 Compounds of Formula (I): or pharmaceutically acceptable (22) PCT Fled: Jun. 25, 2008 salts, Solvates, oresters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic (86) PCT NO.: PCT/US08/07917 syndrome and obesity, neuroinflammatory disorders, cogni tive disorders and psychosis, addiction (e.g., Smoking cessa S371 (c)(1), tion), gastrointestinal disorders, and cardiovascular condi (2), (4) Date: Jun.
    [Show full text]